A Shot in the Arm? FDA Committee To Review Merck and Glaxo HPV Vaccines
This article was originally published in The Pink Sheet Daily
Executive Summary
For Merck, the outcome may mean a long-awaited move to market Gardasil to males; for Glaxo, this may be its chance to sell Cervarix in the U.S.